Abstract: A protein complex isolated from its natural medium and including the ZEBRA protein of sequence SEQ ID NO: 1, the isolated protein complex having the following properties: it is more stable than the ZEBRA protein, in particular it is more resistant to the action of the proteases than the ZEBRA protein, it is capable of specifically binding the AZ125 and AZ130 monoclonal antibodies, it is soluble in a body fluid, and in particular a body fluid selected from the group constituted by blood and serum, and to its detection process and the uses of this process for the prognosis or diagnosis of lymphoproliferative episodes associated with the EBV.

Abstract: Antibodies and antigen-binding molecules directed against Hepatitis C virus (HCV) are presented. The antibodies and antigen-binding molecules specifically bind to the HCV E1E2 complex. Also provided are pharmaceutical compositions containing the antibodies and/or antigen-binding molecules. Nucleic acids encoding the antibodies and antigen-binding molecules, along with corresponding expression vectors and host cells are also provided.

Abstract: A protein complex isolated from its natural medium and including the ZEBRA protein of sequence SEQ ID NO: 1, the isolated protein complex having the following properties: it is more stable than the ZEBRA protein, in particular it is more resistant to the action of the proteases than the ZEBRA protein, it is capable of specifically binding the AZ125 and AZ130 monoclonal antibodies, it is soluble in a body fluid, and in particular a body fluid selected from the group constituted by blood and serum, and to its detection process and the uses of this process for the prognosis or diagnosis of lymphoproliferative episodes associated with the EBV.

Abstract: New conformational antibodies, and more particular conformational monoclonal antibodies and fragments thereof, are directed against HCV. Also provided are compositions of particles that are recognized by such antibodies, and pharmaceutical compositions containing these particles. Also described are HCV enveloped subviral particles and purified HCV enveloped complete viral particles, as well as processes for their preparation.

Abstract: The invention provides new conformational antibodies, and more particular conformational monoclonal antibodies and fragments thereof, that are directed against HCV. Also provided are compositions of particles that are recognized by such antibodies, and pharmaceutical compositions containing these particles. Also described are HCV enveloped subviral particles and purified HCV enveloped complete viral particles, as well as processes for their preparation.

Abstract: An NS5B protein of the hepatitis C virus (HCV), with good replication performance, has a point mutation in at least one of the following positions: in the position corresponding to residue 262 of SEQ ID NO: 1; and/or in the position corresponding to residue 265 of SEQ ID NO: 1; and/or in the position corresponding to residue 316 of SEQ ID NO: 1.

Abstract: Method of using polypeptide derived from ZEBRA protein, or variants or isoforms of the polypeptide for the in vitro and ex vivo screening of the EBV virus reactivation in a biological sample of a subject afflicted by a pathology associated with EBV infection.

Abstract: A process for amplifying hepatitis C virus (HCV) in vivo is provided. The method includes ingesting a viral source by female Aedes vexans or Aedes caspius mosquitoes, and rearing the mosquitoes for a time necessary to amplify the virus.

Abstract: The use of a peptide reagent for detecting the presence or absence of a primary Epstein-Barr virus infection in a patient by testing for IgM antibodies, recognizing said reagent, in a biological sample from the patient according to a per se known method based on the formation of at least one antigen-antibody complex, is disclosed. The reagent contains a peptide recognized by at least one antibody to a peptide having the sequence of formula (II): Leu Glu Ile Lys Arg Tyr Lys Asn Arg Val Ala Ser Arg Lys Cys Arg Ala Lys Phe Lys Gln. The reagent enables such a primary infection to be detected very early.